EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust
Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of
Paul Sekhri Joins Topas Therapeutics as Chairman of the Board
Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election
Caldan Therapeutics Announces Key Appointment
Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel
Harpoon Medical, Inc. Hires Structural Heart Expert Laura Brenton as Vice President of Clinical Affairs
Baltimore, MD, February 21, 2017 – Harpoon Medical, Inc., a clinical stage medical device company focused on the development and commercialization of transcatheter beating heart mitral
Mironid Announces Additional Non-Dilutive Funding Through an Early Stage Award from Innovate UK’s Biomedical Catalyst 2016
Glasgow, Scotland, 30th January 2017: Mironid® Limited, a leader in cell signalling-directed drug discovery, is delighted to start the New Year by initiating a £606K
Sirakoss Announces Two New Patents Granted by the United States Patent and Trademark Office
Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic
Eternygen GmbH Closes € 8.0 million (US$ 8.3m) Series A Financing Led by Epidarex Capital
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3)